Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,000.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective upped by equities research analysts at Guggenheim from $995.00 to $1,000.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s price objective would indicate a potential upside of 47.84% from the company’s current price.

Several other equities research analysts also recently issued reports on the stock. Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 8th. Barclays decreased their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research note on Monday, May 18th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Finally, Leerink Partners reissued a “market perform” rating and set a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $787.88.

Regeneron Pharmaceuticals Trading Up 0.6%

Shares of NASDAQ:REGN traded up $4.25 during midday trading on Tuesday, reaching $676.40. The company’s stock had a trading volume of 48,840 shares, compared to its average volume of 850,427. Regeneron Pharmaceuticals has a 1 year low of $541.00 and a 1 year high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The business has a 50 day moving average price of $640.18 and a 200 day moving average price of $717.26. The firm has a market cap of $71.51 billion, a price-to-earnings ratio of 16.45, a price-to-earnings-growth ratio of 1.50 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same period in the prior year, the firm posted $8.22 earnings per share. The firm’s revenue was up 19.0% on a year-over-year basis. Research analysts forecast that Regeneron Pharmaceuticals will post 37.12 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Wedge Capital Management L L P NC boosted its position in Regeneron Pharmaceuticals by 20.3% during the 2nd quarter. Wedge Capital Management L L P NC now owns 47,775 shares of the biopharmaceutical company’s stock valued at $29,790,000 after purchasing an additional 8,063 shares during the period. Insight Wealth Strategies LLC increased its position in Regeneron Pharmaceuticals by 26.9% in the second quarter. Insight Wealth Strategies LLC now owns 8,734 shares of the biopharmaceutical company’s stock worth $5,456,000 after buying an additional 1,850 shares during the period. Tema ETFs LLC increased its position in Regeneron Pharmaceuticals by 2.3% in the second quarter. Tema ETFs LLC now owns 5,481 shares of the biopharmaceutical company’s stock worth $3,418,000 after buying an additional 121 shares during the period. E. Ohman J or Asset Management AB lifted its stake in Regeneron Pharmaceuticals by 35.2% in the second quarter. E. Ohman J or Asset Management AB now owns 3,840 shares of the biopharmaceutical company’s stock valued at $2,394,000 after buying an additional 1,000 shares during the last quarter. Finally, Harrell Investment Partners LLC lifted its stake in Regeneron Pharmaceuticals by 1.3% in the second quarter. Harrell Investment Partners LLC now owns 2,089 shares of the biopharmaceutical company’s stock valued at $1,303,000 after buying an additional 27 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.